Leen Kawas resigned as Athira's CEO in October 2021 after an investigation into her doctoral work. She's now forging a new path with a life sciences investment firm and telling her side of the story.

Athira Pharma, a small drugmaker focused on neuroscience, is looking into the different paths it could take to “maximizing stockholder value,” after the company’s most advanced experimental ...

Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. The trial found fosgonimeton was no better than placebo on the primary and key secondary ...

Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring. Athira, which went public in 2020 ...

Athira Pharma has been on a bumpy road in recent years, and, now, the company is restructuring and shedding weight to try to keep the journey going. Just a couple of weeks after announcing that ...

BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal ...

Athira Pharma’s stock has sold off some months ago on its Alzheimer’s drug candidate Fosgonimeton not meeting a primary endpoint in a randomized Phase 2 trial. The monotherapy arm did show ...

Athira Pharma’s experimental Alzheimer’s disease drug has failed a Phase 2 clinical trial and the working theory as to why is that the small molecule does not play well with widely prescribed ...

Athira Pharma (NASDAQ:ATHA) shares fell over 75% after the company said fosgonimeton, its experimental therapy for Alzheimer's disease, failed in a Phase 2/3 trial, prompting at least two Wall ...

If you continue to have this issue please contact [email protected]. Back to Healio Athira Pharma Inc. will proceed in 2023 with several clinical trials for treatments for Alzheimer’s ...

“These are not the results we hoped for,” Javier San Martin, MD, Athira’s chief medical officer, acknowledged in a statement. “The lack of clinical decline in the placebo group, combined ...